10-K: Cocrystal Pharma Faces Going Concern Doubt, Clinical Setbacks

Cocrystal Pharma's annual report highlights significant financial challenges, including a going concern doubt and a failed Phase 2a influenza trial, despite progress in other antiviral programs.

Summary

• Cocrystal Pharma, a clinical-stage biotechnology company, is focused on discovering and developing novel antiviral therapeutics for RNA viruses, including influenza, norovirus, coronaviruses, and HCV.
• The company reported a net loss of $8.831 million for the year ended December 31, 2025, an improvement from $17.504 million in 2024.
• Research and development expenses decreased to $5.055 million in 2025 from $12.537 million in 2024, primarily due to the winding down of clinical study costs.
• General and administrative expenses also decreased to $3.964 million in 2025 from $5.341 million in 2024.
• As of December 31, 2025, the cash balance was $7.025 million, down from $9.860 million in 2024, and net cash used in operating activities was $8.192 million.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least the next 12 months due to insufficient working capital.
• The Phase 2a study for oral CC-42344 (Influenza A) failed to yield scientifically viable efficacy results due to unexpectedly low infection rates, leading to a dispute with the CRO for a $6.309 million refund or redo.
• The CDI-988 program (norovirus/coronavirus) showed favorable safety and tolerability in its Phase 1 study, and a Phase 1b challenge study was initiated in February 2026.
• The company raised $5.369 million in net cash from financing activities in 2025 through equity sales, including a registered direct offering and a private placement to accredited investors, some of whom are insiders.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with significant caution due to the explicit 'going concern' doubt, the failure of a key Phase 2a clinical trial, and the ongoing dispute with a CRO, which collectively indicate substantial operational and financial risks despite some progress in other programs.

Positives

• Net loss significantly decreased to $8.831 million in 2025 from $17.504 million in 2024.
• Research and development expenses decreased by $7.482 million in 2025, indicating cost management or completion of certain study phases.
• General and administrative expenses decreased by $1.377 million in 2025.
• CDI-988 (norovirus/coronavirus) Phase 1 study demonstrated favorable safety and tolerability across all doses, including the high-dose 1200 mg cohort.
• Received a Study May Proceed Letter from the FDA in September 2025 for a Phase 1b norovirus challenge study for CDI-988.
• Initiated subject screening for the CDI-988 Phase 1b challenge study in December 2025 and commenced the study in February 2026.
• Received a $500,000 Small Business Innovation Research (SBIR) Phase I award from NIH/NIAID for influenza A and B antiviral development.
• CC-42344 showed potential efficacy against the new Texas avian flu strain in in vitro studies, binding to a highly conserved PB2 region.
• The company's proprietary structure-based drug design platform aims to develop broad-spectrum antivirals with high barriers to drug resistance.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next 12 months due to limited capital and an accumulated deficit of $342.2 million.
• The initial Phase 2a study for oral CC-42344 (Influenza A) failed to yield scientifically viable efficacy results due to unexpectedly low influenza infection among study participants.
• A dispute has arisen with the CRO that performed the CC-42344 Phase 2a study, with the company requesting a $6.309 million refund or redo, and the CRO seeking an additional $600,000.
• The failure of the CC-42344 Phase 2a study has resulted in considerable delays in the Influenza A program and potential loss of the $6.309 million already paid.
• The company has never generated revenue from product sales and does not anticipate doing so for at least four years.
• Cash balance decreased to $7.025 million at December 31, 2025, from $9.860 million at December 31, 2024.
• Net cash used in operating activities was $8.192 million for the year ended December 31, 2025.
• The company will need to raise additional capital in the near future to fund operations and research and development programs.

Risks

• History of losses and may not generate sustained positive cash flow sufficient to fund operations and R&D programs.
• Substantial doubt about the ability to continue as a going concern.
• Need for, and ability to obtain, additional financing when needed on favorable terms, or at all.
• Delays or complications in conducting clinical trials, including the Phase 2a study for oral CC-42344 for the Influenza program which must be redone due to an insufficient infection rate.
• Clinical studies may not yield favorable results, or earlier clinical results of effectiveness and safety may not be adequate, reproducible, or indicative of future results.
• Risks inherent in developing, obtaining regulatory approvals for, and commercializing new, commercially viable, and competitive products and treatments, including evolving regulatory requirements and market acceptance.
• Research and development activities may not result in commercially viable products.
• Performance of third-party distribution partners, licensees, and manufacturers, including the ability of CROs to recruit volunteers for clinical studies.
• Increased competition, including the possibility that competitors may develop effective and/or less costly treatments or vaccines.
• Success is dependent on the involvement and continued efforts of the Chairman and Co-Chief Executive Officers.
• Information technology systems may be subject to unauthorized tampering, cyberattack, or other data security or privacy incidents.
• Failure to maintain the security of patient-related information.
• Ability to obtain and maintain intellectual property protection for products.
• Ability to defend intellectual property rights and operate without infringing others' IP.
• Ability to attract and retain key scientific and management personnel.
• Failure to obtain and maintain regulatory approval for products and services.
• Legal, economic, political, regulatory, currency exchange, and other risks associated with international operations.
• Possibility of a recession or other adverse consequences in the U.S. or other countries, impacting capital access and R&D efforts.
• Disruptions to operations from uncontrollable events such as geopolitical conflicts.
• The novel approach to drug discovery may never lead to marketable products.
• May not successfully identify and implement an alternative product development strategy and may cease operation.
• Future commercial success depends on gaining regulatory approval, which is a lengthy and uncertain process.
• Product candidates may cause adverse effects or have other properties that could delay or prevent regulatory approval or limit market acceptance.
• Extensive regulatory requirements and potential future development and regulatory difficulties even after approval.
• May not succeed in obtaining or maintaining necessary rights to drug compounds and processes through acquisitions and in-licenses.
• Third parties may be developing competitive products without knowledge, which may prove superior.
• Limited experience in conducting and managing preclinical development activities and clinical trials.
• Reliance on third-party manufacturers and limited sources of supply for drug substances and products.
• Business could be negatively impacted by cybersecurity threats and other security threats and disruptions.
• Artificial intelligence presents risks and challenges, and the decision not to implement AI may put the company at a competitive disadvantage.
• Commercial success depends on acceptance by the medical community and healthcare payors.
• Inadequate insurance and/or government coverage and reimbursement could impair profitability.
• Uncertainty due to the 2025 inauguration of a new presidential administration in the U.S., potentially leading to reduced government funding and delays at regulatory agencies.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties.
• Potential product liability claims.
• Business interruptions from pandemics, natural disasters, and adverse weather events.
• Stock price and trading volume historically volatile, with increases potentially temporary.
• Future issuances of common stock or rights could cause additional dilution and stock price fall.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• May not attract the attention of major brokerage firms.
• Issuance of preferred stock could make acquisition more difficult and depress stock price.
• Bylaws provide for exclusive forum in Delaware courts for certain disputes, which may limit stockholder ability to bring claims.

Future Outlook

The company plans to continue development of oral CC-42344 for influenza A, subject to resolving the dispute with the CRO or raising additional capital for a new Phase 2a study. Preclinical development for an inhaled CC-42344 formulation is progressing. The CDI-988 program is advancing with a Phase 1b norovirus challenge study underway. The company anticipates needing to raise additional capital to fund future operations and R&D, as it expects to incur substantial operating losses and negative cash flows for the foreseeable future. The goal for HCV treatment is to develop ultra-short combination oral treatments of four to six weeks.

Management Comments

• "We employ unique structure-based technologies and Nobel Prize winning expertise with the goal of creating viable antiviral drugs."
• "Our goals include treating and preventing influenza virus, norovirus, and coronavirus infections by discovering and developing direct-acting antiviral drug candidates targeting required steps in the viral replication process."
• "We believe CDI-988 represents the only oral pan-viral antiviral in development for the treatment and prevention of viral gastroenteritis caused by noroviruses, and coronaviruses, including SARS-CoV-2 and its variants."
• "Management determined that the low infectivity obtained in this study hindered antiviral data analysis."
• "We expect that our reported cash balance is not be sufficient to support the Companys working capital needs for the 12 months following the filing of this Report, taking into account our intended research and development efforts in 2025. As a result, we need to raise additional capital to support our ongoing and anticipated working capital needs."
• "Management intends to fund future operations through additional private or public equity offerings and through arrangements with strategic partners or from other sources."
• "Our Co-Chief Executive Officer, Dr. Sam Lee, is actively involved in monitoring our research and development activities and our clinical trial program."

Industry Context

StockSavvy.ai notes that Cocrystal Pharma operates in a highly competitive and rapidly evolving biotechnology and pharmaceutical landscape, particularly in antiviral development. The focus on broad-spectrum antivirals with high barriers to resistance is a strategic response to the persistent challenge of viral mutations, as seen with influenza and COVID-19 variants. While larger competitors like Roche, Gilead, and Merck have established products and significantly greater resources, Cocrystal's proprietary structure-based drug design platform aims to differentiate its candidates. The ongoing global health concerns around influenza, coronaviruses, and noroviruses underscore the significant unmet medical needs the company is addressing. However, the industry also faces increasing regulatory scrutiny, cost containment pressures from payors, and the potential impact of new technologies like AI, which some competitors are already leveraging.

Comparison to Industry Standards

• Current approved antiviral treatments for influenza (e.g., Tamiflu, Relenza, Xofluza) are effective but burdened with significant viral resistance, with strains resistant to oseltamivir appearing and sometimes predominating (e.g., 2009 swine influenza pandemic). Cocrystal's CC-42344 aims for a high barrier to resistance.
• For COVID-19, approved treatments include Veklury (remdesivir) and Paxlovid, with several antibody and antiviral therapeutics under EUA. Cocrystal's CDI-988 aims to be an oral pan-viral treatment for coronaviruses and noroviruses, potentially offering a broad-spectrum advantage.
• In the norovirus space, there is currently no effective treatment or vaccine, presenting a significant unmet medical need. Cocrystal's CDI-988 is in a Phase 1b human challenge study, positioning it as a potential first-in-class therapeutic. Competitors like Vaxart Pharmaceutical, Moderna, Hillevax, Takeda Pharmaceuticals, Anhui Zhifei Longcom Biopharmaceutical (China), and National Vaccine and Serum Institute (China) are developing vaccines.
• The HCV market is highly competitive with several approved DAAs (e.g., Harvoni, Viekira Pak, Epclusa, Zepatier, Mavyret) offering 8-12 week treatments. Cocrystal's CC-31244 aims for ultra-short combination oral treatments of four to six weeks, which would be a significant improvement over current standards if successful. To our knowledge no competing company has yet developed a short HCV treatment of less than 8 weeks with a high (>95%) sustained virologic response (SVR) at week 12.

Management Changes

Corporate Governance

Legal Proceedings

• A dispute has arisen with the United Kingdom clinical research organization (CRO) that performed the Phase 2a study for CC-42344. The company contends the CRO breached its agreement and is requesting a refund of $6,309,000 or a redo of the study. The CRO implicitly denied liability and is seeking to recover an additional approximately $600,000 from the company. The company appears to be seeking arbitration.

Related Party Transactions

• On August 14, 2024, the company entered into a three-year lease extension for its Miami, Florida office with a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder. Total rent and other expenses paid in connection with this lease were $63,000 in 2025 and $62,000 in 2024.
• On October 28, 2025, four accredited inside investors (insiders of the company) purchased a total of 743,024 units of the company's securities for gross proceeds of $1.032 million.
• On April 4, 2023, the company entered into a Securities Purchase Agreement with two accredited investors, including Frost Gamma Investments Trust (controlled by Dr. Phillip Frost) and Fred Hassan (appointed director weeks later), for 1,015,229 shares each at $1.97 per share, totaling two equal $2,000,000 investments.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future equity raises, potential loss of investment due to going concern doubt, and volatility in stock price. The dispute with the CRO and the failure of the CC-42344 trial represent a setback for a key program.
• Employees: The company has 10 full-time employees, with 8 in R&D. Continued losses and capital needs could impact job security or future compensation.
• Customers (future): Potential for novel antiviral treatments for influenza, norovirus, coronaviruses, and HCV, offering new therapeutic options if successfully developed and commercialized.
• Suppliers/CROs/CMOs: The dispute with the UK CRO highlights risks in third-party relationships. Future R&D efforts depend on reliable third-party services.
• Creditors: The "going concern" doubt raises concerns about the company's ability to meet its financial obligations.

Next Steps

• Seek to arbitrate the dispute with the CRO regarding the failed CC-42344 Phase 2a study.
• Conduct a new Phase 2a study for oral CC-42344 as a treatment for pandemic and seasonal influenza A, subject to capital availability or dispute resolution.
• Continue preclinical development of an inhaled formulation of CC-42344.
• Continue the Phase 1b challenge study for CDI-988 as a norovirus preventive and treatment at Emory University School of Medicine.
• Seek a partner for further clinical development of CC-31244 (HCV).
• Raise additional capital through private or public equity offerings or strategic partnerships to fund future operations and R&D.
• Evaluate ASU 2024-03 to determine its impact on financial statement presentation and disclosures.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt about our ability to continue as a going concern' and that current cash is 'not be sufficient to fund our operations beyond the next 12 months.' This fundamental financial instability is compounded by the complete failure of a key Phase 2a clinical trial for its lead influenza candidate (CC-42344) to yield viable efficacy data, leading to a significant financial dispute with the CRO. While there are some positive developments in other programs and cost reductions, the immediate and severe financial distress, coupled with a major clinical setback and the need for substantial dilutive capital raises, presents an extremely high-risk profile. Seasoned investors would likely view these factors as critical red flags, warranting an immediate exit to preserve capital.

Keywords

Antiviral Therapeutics, Clinical-Stage Biotech, Influenza A, Norovirus, Coronaviruses, SARS-CoV-2, Hepatitis C, Drug Discovery, Clinical Trials, SEC Filing, Biotechnology, Pharmaceutical, COCP, Going Concern, Capital Raise, Drug Development, RNA Viruses, CC-42344, CDI-988, CC-31244, FDA Approval, Intellectual Property